Some analysts estimate that more than 100 incretin-modulating candidates, across GLP-1, GIP, glucagon, amylin, and novel multi-agonist combinations, are now in development. Over 50 companies are vying for a slice of this opportunity, from biotechnology newcomers to multinational giants. …
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
Georgia Forrest
New Stories
-
Australians turn to local pharmacies as frontline of everyday healthcare
March 13, 2026 - - Latest News -
Sandoz and Camp Quality unite to strengthen support for Australian families facing childhood cancer
March 13, 2026 - - Latest News -
The leadership challenge behind Australia’s medicine access gap
March 13, 2026 - - Latest News -
Australia has spent four decades having the wrong conversation about medicines access
March 13, 2026 - - Latest News -
‘An absolute medical miracle’ - MPs highlight progress and challenges at Cystic Fibrosis event
March 13, 2026 - - Latest News -
Australia’s top community pharmacists honoured at national awards
March 13, 2026 - - Latest News -
A new prostate cancer technology moves closer to global trials after strong early results
March 12, 2026 - - Australian Biotech